Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541384 | 1.00 | LRRK2 (0.45) | LRRK2CXCR4CNR2NR1H2CYP1A2 | |
| SCHEMBL15397172 | 0.96 | LRRK2 (0.44) | LRRK2CXCR4CNR2NR1H2 | |
| SCHEMBL10145297 | 0.85 | CNR2 (0.49) | LRRK2CXCR4CNR2CYP1A2CYP2D6 | |
| SCHEMBL541576 | 0.84 | LRRK2 (0.43) | LRRK2CXCR4CNR2NR1H2CYP1A2 | |
| SCHEMBL541575 | 0.84 | LRRK2 (0.43) | LRRK2CXCR4CNR2NR1H2CYP1A2 | |
| SCHEMBL12796227 | 0.84 | LRRK2 (0.48) | LRRK2CXCR4CNR2NR1H2CYP1A2 | |
| SCHEMBL10146178 | 0.83 | LRRK2 (0.47) | LRRK2CXCR4CNR2CYP1A2CYP2D6 | |
| SCHEMBL542027 | 0.83 | CCR3 (0.49) | CXCR4CNR2CYP2D6CYP2C19 | |
| SCHEMBL542026 | 0.83 | CCR3 (0.49) | CXCR4CNR2CYP2D6CYP2C19 | |
| SCHEMBL10145329 | 0.82 | LRRK2 (0.44) | LRRK2CXCR4CNR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | LRRK2 1659/4885CXCR4 350/4885CNR2 1/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | LRRK2 1707/4885CXCR4 206/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.